Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care

This serves as a white paper by the North American Neuroendocrine Tumor Society (NANETS) on the practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. The authors involved in the development of this manuscript represent a multidisciplinary team of patient advocacy, palliative care, and hospice care practitioners, endocrinologist, and oncologists who performed a literature review and provided expert opinion on a series of questions often asked by our patients and patient caregivers affected by this disease. We hope this document serves as a starting point for oncologists, palliative care teams, hospice medical teams, insurers, drug manufacturers, caregivers, and patients to have a frank, well-informed discussion of what a patient needs to maximize the quality of life during a routine, disease-directed care as well as at the end-of-life.

[1]  B. Niederle,et al.  How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? , 2021, Current Oncology Reports.

[2]  A. La Salvia,et al.  Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. , 2021, Comprehensive psychiatry.

[3]  D. Fraker,et al.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma , 2021, Pancreas.

[4]  J. Potter,et al.  Palliative Sedation, Compassionate Extubation, and the Principle of Double Effect: An Ethical Analysis , 2021, The American journal of hospice & palliative care.

[5]  Siming Jia,et al.  A case–control study , 2021 .

[6]  A. Trojani,et al.  Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors , 2020, Nutrition and cancer.

[7]  D. Metz,et al.  Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. , 2020, Pancreas.

[8]  E. Bruera,et al.  Recommendations for Palliative and Hospice Care in NCCN Guidelines for Treatment of Cancer. , 2020, The oncologist.

[9]  J. Hallet,et al.  Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors , 2020, World Journal of Surgery.

[10]  D. Metz,et al.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.

[11]  E. Bruera,et al.  Redefining Palliative Care—A New Consensus-Based Definition , 2020, Journal of pain and symptom management.

[12]  E. Bruera,et al.  Models of Palliative Care Delivery for Patients With Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Bennett,et al.  Practice review: Evidence-based and effective management of pain in patients with advanced cancer , 2020, Palliative medicine.

[14]  S. Singh,et al.  Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. , 2019, The oncologist.

[15]  J. Hallet,et al.  Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes , 2019, Annals of Surgical Oncology.

[16]  J. Wills,et al.  Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  J. Pratschke,et al.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract , 2018, Reviews in Endocrine and Metabolic Disorders.

[18]  D. Metz,et al.  Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS) , 2018, Neuroendocrinology.

[19]  Y. Mineur,et al.  Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice , 2018, Neuropsychopharmacology.

[20]  M. Spampatti,et al.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important , 2018, Reviews in Endocrine and Metabolic Disorders.

[21]  P. Lapuerta,et al.  Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial , 2018, Endocrine-related cancer.

[22]  P. Ma,et al.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas , 2017, Neoplasia.

[23]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[24]  D. Meier,et al.  Defining Advance Care Planning for Adults: A Consensus Definition From a Multidisciplinary Delphi Panel. , 2017, Journal of pain and symptom management.

[25]  H. Sorbye,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents , 2017, Neuroendocrinology.

[26]  E. Wolin,et al.  Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors , 2017, Pancreas.

[27]  B. Judson,et al.  Treatment delay and facility case volume are associated with survival in early‐stage glottic cancer , 2017, The Laryngoscope.

[28]  P. Hellman,et al.  Clinical signs of fibrosis in small intestinal neuroendocrine tumours , 2017, The British journal of surgery.

[29]  C. Stanciu,et al.  Loperamide, the “Poor Man’s Methadone”: Brief Review , 2017, Journal of psychoactive drugs.

[30]  V. C. Kok,et al.  Management of Hypoglycemia in Nondiabetic Palliative Care Patients: A Prognosis-Based Approach , 2016, Palliative care.

[31]  R. Riechelmann,et al.  Complications from carcinoid syndrome: review of the current evidence , 2016, Ecancermedicalscience.

[32]  E. Bruera,et al.  Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review , 2016, The oncologist.

[33]  M. Pavel,et al.  Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs , 2016, Journal of global oncology.

[34]  G. Lemmens,et al.  May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report , 2016, Acta oncologica.

[35]  L. Ellegård,et al.  Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET) , 2016, European Journal of Clinical Nutrition.

[36]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  E. D. de Vries,et al.  Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor , 2015, Neuroendocrinology.

[38]  Richard S Levene,et al.  Hypoglycemia management in nondiabetic adults at the end of life #291. , 2015, Journal of Palliative Medicine.

[39]  C. Peruselli [Early palliative care]. , 2015, Recenti progressi in medicina.

[40]  Mark T Hegel,et al.  Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Kennecke,et al.  Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors , 2015, Cancer Medicine.

[42]  Feng Yang,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[43]  B. Boulay,et al.  Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. , 2014, World journal of gastroenterology.

[44]  Allan Donner,et al.  Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial , 2014, The Lancet.

[45]  W. Drake,et al.  Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. , 2010, QJM : monthly journal of the Association of Physicians.

[46]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .

[47]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Connor Development of Hospice and Palliative Care in the United States , 2008, Omega.

[49]  K. Iwasaki,et al.  Comparing hospice and nonhospice patient survival among patients who die within a three-year window. , 2007, Journal of pain and symptom management.

[50]  Xinjun Li,et al.  Incidence trends and risk factors of carcinoid tumors , 2001, Cancer.

[51]  J. Rastad,et al.  Method for Dissection of Mesenteric Metastases in Mid-gut Carcinoid Tumors , 2000, World Journal of Surgery.

[52]  J. Ajani,et al.  Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  G. Gill,et al.  Diazoxide treatment for insulinoma: a national UK survey. , 1997, Postgraduate medical journal.

[54]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[55]  J. Farndon,et al.  Diazoxide in the management of patients with insulinoma , 1986, World Journal of Surgery.

[56]  E. Keat,et al.  Carcinoid Heart Disease , 1974, Proceedings of the Royal Society of Medicine.

[57]  A. Vinik,et al.  Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. , 2018, The oncologist.

[58]  Kjell Öberg,et al.  Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Thomas J. Smith,et al.  Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Eva Segelov,et al.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors , 2017, Pancreas.

[61]  K. Oberg,et al.  The management of neuroendocrine tumours: current and future medical therapy options. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[62]  M. Caplin,et al.  Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. , 2005, Best practice & research. Clinical gastroenterology.

[63]  G. Hartmann The Role of Diet , 1982 .

[64]  A. Bornstein,et al.  Carcinoid Tumors , 2006 .